New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
09:12 EDTSTXS, DRTX, MRVL, RBCN, ARTX, MDR, CLNE, ISRG, UAL, VRNT, HSP, MDCO, NVDAOn The Fly: Pre-market Movers
HIGHER: Intuitive Surgical (ISRG), up 10% after announcing FDA clearance for new da Vinci Xi Surgical System... Clean Energy (CLNE), up 4% after beginning fueling at two stations, signing agreements... Durata Therapeutics (DRTX), up 8% after an FDA Committee voted in favor of its Dalvance injection for the treatment of certain acute bacterial skin and skin structure infections... Rubicon (RBCN), up 7.9% following upgrade at JPMorgan... United Continental (UAL), up 2.2% following upgrade at UBS... NVIDIA (NVDA), up 3% after upgrade at JMP Securities... Marvell (MRVL), up 4% after announcing it plans to appeal patent decision against it... Stereotaxis (STXS), up 12% after submitting 510 Premarket Notification with the FDA for the Vdrive Robotic system... Verint Systems (VRNT), up 5% after reporting earnings that beat expectations and providing a fiscal year outlook that also topped estimates. LOWER: Arotech (ARTX), down 11% after reporting fiscal year earnings and revenue that disappointed... The Medicines Company (MDCO), down 16% after court ruled the company failed to prove that Hospira's (HSP) generic Angiomax product infringed its patents... McDermott (MDR), down 5.8% after filing to sell 10M tangible equity units and saying that its first quarter results may differ "substantially" from the company's expectation.
News For UAL;RBCN;NVDA;ISRG;MRVL;MDCO;CLNE;DRTX;HSP;MDR;STXS;VRNT;ARTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 19, 2014
09:01 EDTVRNTBig data for security could reach $4B-$5B, says FBR Capital
Subscribe for More Information
08:39 EDTVRNTVerint Systems forms strategic partnership with Unify
Subscribe for More Information
07:36 EDTMRVLMarvell volatility elevated into Q1 and outlook
Subscribe for More Information
November 17, 2014
18:25 EDTUALSkyWest sees Q4 pre-tax charge of $55M-$70M
Subscribe for More Information
08:02 EDTDRTXActavis completes Durata Therapeutics tender offer
Subscribe for More Information
07:52 EDTNVDADepartment of Energy awards $425M for supercomputing technologies
Subscribe for More Information
07:21 EDTHSPDanone mulls IPO for nutrition unit as sale talks disappoint, Reuters says
Subscribe for More Information
06:13 EDTUALUnited Continental says 2,500 flight attendants to leave early, Crain's reports
Subscribe for More Information
November 16, 2014
13:41 EDTMDCOThe Medicines Co. presents findings from MDCO-216 study
The Medicines Company presented findings from a new Phase 1 study showing that a single infusion of MDCO-216, an investigational lipid-modifying agent, in both healthy and CAD patients, modified key lipid parameters including ApoA-1, phospholipids, HDL, pre-beta 1 HDL and Apo E, markedly increased ABCA1 mediated efflux, a potential marker of reverse cholesterol transport and was well tolerated. The study was presented today as part of a poster session at The American Heart Association’s Annual Scientific Sessions in Chicago. Clinical findings have shown that human carriers of the ApoA-1 Milano variant have a reduced incidence of cardiovascular disease. MDCO-216, currently under development by The Medicines Company, is a complex of recombinant human Apo A1 with phospholipids to emulate an HDL particle. MDCO-216 has the potential to modify atherosclerotic disease by promoting reverse cholesterol transport, and its potential impact on reducing cardiovascular events in acute coronary syndrome, ACS, patients. “This study provides a signal that MDCO-216 is able to modulate lipid parameters consistent with those humans with the ApoA-1 variant, had an important effect on markers of reverse cholesterol transport such as pre-beta1 HDL and ABCA1 mediated efflux, and importantly was well-tolerated,” commented David Kallend, MBBS, Vice President and Global Medical Director for the Lipid Programs at The Medicine Company. “These findings support the continued development of MDCO-216 as a potential treatment to help address a currently unmet need in coronary artery disease patients."
November 14, 2014
16:52 EDTMRVLGreenlight Capital gives quarterly update on stakes
Subscribe for More Information
12:53 EDTUALOmega Advisors gives quarterly update on stakes
NEW STAKES: AerCap Holdings (AER), Nordic American Offshore (NAO), Melco Crown Entertainment (MPEL), Groupon (GRPN), and Ashland (ASH). INCREASED STAKES: QEP Resources (QEP), United Continental (UAL), Cabot Oil & Gas (COG), Actavis (ACT), and KAR Auction Services (KAR). DECREASED STAKES: Sprint (S), SandRidge Energy (SD), Sirius XM Holdings (SIRI), Kinder Morgan (KMI), and Transocean (RIG). LIQUIDATED STAKES: QUALCOMM (QCOM), Ocwen Financial (OCN), Freeport-McMoRan (FCX), Boston Scientific (BSX), and Capital One (COF).
10:33 EDTMDCOThe Medicines Co. to present new data on MDCO-216 at AHA sessions
Subscribe for More Information
07:14 EDTHSPAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
10:01 EDTVRNT, MRVLOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ATK (ATK) downgraded to Hold from Buy at Argus... Adeptus Health (ADPT) downgraded to Hold from Buy at Deutsche Bank... American Woodmark (AMWD) downgraded to Neutral from Buy at Longbow... Avnet (AVT) downgraded to Sell from Neutral at Goldman... Baxano Surgical (BAXS) downgraded to Sell from Buy at Summer Street... Beazer Homes (BZH) downgraded to Neutral from Overweight at JPMorgan... Bristol-Myers (BMY) downgraded to Equal Weight from Overweight at Morgan Stanley... Centene (CNC) downgraded to Market Perform from Outperform at FBR Capital... Cherry Hill Mortgage (CHMI) downgraded to Equal Weight from Overweight at Barclays... Discover (DFS) downgraded to Hold from Buy at Deutsche Bank... Fleetmatics (FLTX) downgraded to Neutral from Buy at BofA/Merrill... Gazprom (OGZPY) downgraded to Neutral from Overweight at JPMorgan... Jabil Circuit (JBL) downgraded to Neutral from Buy at Goldman... LabCorp (LH) downgraded to Hold from Buy at Deutsche Bank... Laredo Petroleum (LPI) downgraded at BMO Capital... Macy's (M) downgraded to Market Perform from Outperform at Wells Fargo... Madison Square Garden (MSG) downgraded to Equal Weight from Overweight at Morgan Stanley... Marvell (MRVL) downgraded to Sell from Neutral at Goldman... Meritor (MTOR) downgraded to Neutral from Overweight at Piper Jaffray... Swedbank (SWDBY) downgraded to Underperform from Sector Perform at RBC Capital... TransGlobe (TGA) downgraded to Sector Perform from Outperform at Scotia Capital... UIL Holdings (UIL) downgraded to Hold from Buy at Argus... Verint Systems (VRNT) downgraded to Fair Value from Buy at CRT Capital... ZAIS Financial (ZFC) downgraded to Equal Weight from Overweight at Barclays.
08:28 EDTVRNTVerint Systems downgraded to Fair Value at CRT Capital
Subscribe for More Information
07:27 EDTMRVLMarvell volatility elevated into Q1 and outlook
Subscribe for More Information
06:46 EDTVRNTVerint Systems downgraded to Fair Value from Buy at CRT Capital
Subscribe for More Information
05:28 EDTMRVLMarvell downgraded to Sell from Neutral at Goldman
Subscribe for More Information
November 12, 2014
12:55 EDTNVDANVIDIA says Samsung files counter-suit, patent infringement claims
Subscribe for More Information
07:56 EDTCLNERyder signs alliance agreement with Mansfield Clean Energy Partners
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use